Disclaimer: Please note the below information is for our patients and service users who are interested in the research we are currently participating in. This is not a recruitment page. If appropriate, your GP will invite you to participate in a research study on a case by case basis. It is not possible to request access to a study.
Click on the below titles to find out more
Dementia Research is a service which allows people to register their interest in national dementia research.
It helps people with dementia, their carers, or anyone interested in dementia research to be matched to studies. Once registered, your details will be stored securely, and will be regularly checked to see if you match to studies. Find out more here: www.joindementiaresearch.nihr.ac.uk
Recruit for studies on common diseases, rare diseases and even healthy populations. Due to the specialist work needed to support COVID research we have a special section for that too. We can recall members who wish to take part in further studies.
Find out more here: www.bioresource.nihr.ac.uk
This study aims to find out whether people with chronic kidney disease (CKD) should take daily low-dose aspirin to reduce the risk of a first heart attack or stroke (cardiovascular disease, CVD).
We want to determine whether aspirin should be given to people with CKD to prevent a first heart attack or stroke (primary prevention). As CVD is more common in people with CKD than in the general population we would expect aspirin to be of greater benefit, but the risks of bleeding may also be higher. Before we can recommend aspirin for primary prevention in people with CKD we need to be sure that the benefits outweigh the possible risks.
Have PCOS and trying for a baby? Join our LOCI research trial!
We are looking for women with polycystic ovary syndrome (PCOS) who are trying to conceive, to take part in a new clinical trial, called ‘LOCI’. LOCI is investigating the effectiveness of two different drugs (letrozole and clomifene) on fertility, pregnancy and successful births. Both of these drugs aim to induce or ‘switch on’ ovulation, which is often disrupted in women with PCOS. Improved ovulation should increase the chances of becoming pregnant. Clinicians and researchers do not yet know which should be the first-line medication.
Women in the study will take part in up to 6 treatment cycles where letrozole or clomifene is taken with or without (placebo) the drug metformin. These drugs are already widely used and considered safe, but the results of LOCI will provide important insights on which combination of drugs works best – something which is still unknown. By taking part in this trial you will be helping our research team move science forwards and giving many women with PCOS a better chance of getting pregnant and giving birth in future. During your involvement, you will be monitored by your clinical team and treated with respect and dignity throughout. Your data will be kept confidential at all times and you are free to leave the study at any time.
We welcome women of any ethnicity or background to take part. If language or access barriers are an issue, please let us know as we would like to facilitate your participation wherever possible e.g. providing an interpreter to help. To find out more you can check our website https://www.birmingham.ac.uk/loci and/or contact us on
Although we know that supported self-management helps people live with their asthma it isn’t widely provided: fewer than 1 in 4 people who replied to an Asthma UK web survey owned an asthma action plan. There are many reasons why self-management is not more widely used. These include:
1) lack of resources available for patients
2) healthcare professionals not possessing the right skills
3) the way that asthma management is organised in the health service.
The IMP2ART programme of work has developed a new approach to target all three areas.
Multi-centre randomised controlled trial of integrated therapist and online CBT (Cognitive behavioural therapy) for depression in primary care.
Aminosalicylate agents have proven effective for inducing and maintaining remission in mild to moderate Ulcerative Colitis and thus are commonly used as first-line agents for patients with Crohn's Disease in remission. However, there is uncertainty regarding their effectiveness for Crohn’s Disease.
The majority of women with Type 2 diabetes currently become pregnant without meeting current NICE care guidelines, putting their babies and personal health at risk. This study aims to address this problem by introducing a new care template for practices to support routine diabetes consultations with women of childbearing age. Participating practices would also be given access to a short online training programme on pregnancy care in diabetes. Following the introduction of the care templates we would monitor their impact on the delivery of the embedded care processes at regular intervals. We will also be collecting data from local hospitals to estimate the number of women presenting antenatally who meet current NICE guidelines.